Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Where the money is

It was US investors that largely bankrolled the biotech industry over the past 25 years. Is all that about to change? Michael Fitzgerald investigates.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The amount of capital raised by biotech through IPOs over the past ten years.
Figure 2: The amount of capital raised by biotech through follow-on offerings over the past ten years.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fitzgerald, M. Where the money is. Nat Biotechnol 24, 240–242 (2006). https://doi.org/10.1038/nbt0306-240

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0306-240

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing